Endoscopic retrograde cholangiopancreatography (ERCP) is now well established in the diagnosis and treatment of biliary and pancreatic disorders. Although the procedure is generally considered to be safe, complications related to cannulation, contrast injection, and sphincterotomy may occur, and include cholangitis, haemorrhage, perforation, and pancreatitis.' 2 Pancreatitis is the most common of these complications. Clinically severe pancreatitis is reported to occur in 1-7% of patients,'-' while an asymptomatic increase in pancreatic enzyme activities may occur in up to 70%. 6 Various gastrointestinal hormones such as glucagon and calcitonin have been investigated in studies on the prevention of ERCP induced pancreatitis.7-Somatostatin and a long acting analogue, octreotide, have received particular attention recently. Both are potent known inhibitors of pancreatic secretion. Several studies in healthy volunteers have shown inhibition of baseline and stimulated exocrine pancreatic secretion."'-'2 Four animal studies of experimentally induced acute pancreatitis have shown an improvement in the pancreatic enzyme response after the infusion of cyclic somatostatin or octreotide.'3"'-Three of the four studies showed a concomitant improvement in histology. ' Repeated pancreatic duct injections 45 34 Pancreatic duct overfilling 22 16 Papillary 'pre-cut' (Table I) . ERCP results are shown in Table II . Cannulation of the papilla failed in nine patients. The pancreatic duct was filled in 199 patients (84%). The octreotide and placebo groups were similar in terms of pancreatic duct filling, number of pancreatic duct injections, volume of contrast media injected, and pancreatic duct overfilling producing acinar opacification. Therapeutic ERCP procedures (39 sphincterotomies and 13 endoprostheses placements) were performed in 18% of patients.
The numbers of patients in the octreotide and placebo groups with 'easy' and 'difficult' cannulations of the bile and pancreatic ducts is given in Figure 1 .
The diagnostic findings at ERCP are detailed in Table III .
Five patients (2%) developed ERCP associated pancreatitis -three in the octreotide and two in the placebo groups. Table IV Comparison of the median serum amylase and lipase activities at baseline and at eight and 24 hours after ERCP in the octreotide and placebo groups showed no significant differences between the two treatment groups (Fig 2) .
Excluding those patients who developed pancreatitis, 43 (18%) developed non-specific post ERCP abdominal pain -21 in the octreotide and Eight of nine cases of failed papillary cannulation were in the octreotide group, and patients in the octreotide group tended to have fewer 'easy' as well as more 'difficult' cannulations of the bile and pancreatic ducts (Fig 1) . This raises the question of whether octreotide increases sphincter of Oddi pressure, rendering ductal cannulation more difficult. The effect of somatostatin on the human sphincter of Oddi has not been established. We studied the effect of octreotide administered in a dose of 50 Fig on the sphincter of Oddi using endoscopic manometry in seven patients and found that this hormone increased basal pressure and the frequency of phasic wave contractions appreciably. 30 In the prairie dog and rabbit, somatostatin has been shown to inhibit sphincter of Oddi motility,332 but this effect may be species specific. The gastrointestinal hormone cholecystokinine has been shown to have an opposite effect on the human sphincter of Oddi compared with that of the rabbit and prairie dog. [32] [33] [34] [35] Excitatory effects of somatostatin or octreotide on the sphincter of Oddi may impair biliary and pancreatic duct outflow. Such a mechanism is indirectly supported by human studies showing that cholecystokinin, a hormone with antagonistic properties to somatostatin on the sphincter of Oddi,3237 increases bile flow into the duodenum.3537 One study of experimental pancreatography in anaesthesised piglets showed that somatostatin significantly delayed ductal emptying of contrast media compared with control animals. 22 Based on the above considerations, it is possible that a pancreatic protective effect of octreotide as shown in experimental models of pancreatitis'3l-6 may be clinically offset by an increase of sphincter of Oddi pressure leading to pancreatic duct outflow obstruction. More difficult cannulation at ERCP resulting in papillary oedema may contribute to outflow obstruction. The administration of somatostatin or octreotide after complete emptying of the contrast media filled pancreatic duct may produce different results.
Despite the large number of patients recruited for this study, from a purely statistical standpoint a significantly larger number of subjects would be required to eliminate a type II error in a negative study due to the low incidence of ERCP induced clinical pancreatitis. Such a study would clearly be a major undertaking, and might be difficult to justify in view of mixed results in smaller studies. Studies evaluating somatostatin or octreotide in therapeutic ERCP procedures associated with a higher incidence of pancreatitis, such as manipulation of the pancreatic duct sphincter with hydrostatic balloon dilators,2' would be better suited for future studies.
